The new Alzheimer’s drug Aduhelm will not be covered by Blue Cross Blue Shield of Rhode Island. In an email, Jill Flaxington, a representative for BCBSRI, Rhode Island’s largest private health insurer, noted that the company is awaiting a decision from the Centers for Medicare & Medicaid Services on Medicare coverage. “BCBSRI will evaluate our coverage decisions when more clinical data becomes available to determine whether [Aduhelm] achieves clearly shown clinical value and safety,” BCBSRI says of its assessment process.